Transcriptional Interactomic Inhibition of RORα Suppresses Th17-Related Inflammation

References

• Azizi G, Jadidi‐Niaragh F, Mirshafiey A. Th17 cells in immunopathogenesis and treatment of rheumatoid arthritis. Int J Rheum Dis. 2013;16(3):243–253. doi:10.1111/1756-185X.12132
   PubMed Web of Science ®Google Scholar
• Moser T, Akgün K, Proschmann U, Sellner J, Ziemssen T. The role of TH17 cells in multiple sclerosis: therapeutic implications. Autoimmun Rev. 2020;19:102647. doi:10.1016/j.autrev.2020.102647
   PubMed Web of Science ®Google Scholar
• Martin JC, Baeten DL, Josien R. Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus. Clin Immunol. 2014;154(1):1–12. doi:10.1016/j.clim.2014.05.004
   PubMed Web of Science ®Google Scholar
• Zhao J, Lu Q, Liu Y, et al. Th17 Cells in inflammatory bowel disease: cytokines, plasticity, and therapies. J Immunol Res. 2021;2021:1–14. doi:10.1155/2021/8816041
   Web of Science ®Google Scholar
• Aujla SJ, Dubin PJ, Kolls JK. Th17 cells and mucosal host defense. Paper presented at: Seminars in immunology; 2007.
   Google Scholar
• Singh RP, Hasan S, Sharma S, et al. Th17 cells in inflammation and autoimmunity. Autoimmun Rev. 2014;13(12):1174–1181. doi:10.1016/j.autrev.2014.08.019
   PubMed Web of Science ®Google Scholar
• Zhang Y-Z, Li -Y-Y. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20(1):91. doi:10.3748/wjg.v20.i1.91
   PubMed Web of Science ®Google Scholar
• Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329–342. doi:10.1038/nri3661
   PubMed Web of Science ®Google Scholar
• Gálvez J. Role of Th17 cells in the pathogenesis of human IBD. Int Scholar Res Notices. 2014;2014:928461.
   Google Scholar
• Serra HG, Duvick L, Zu T, et al. RORα-mediated Purkinje cell development determines disease severity in adult SCA1 mice. Cell. 2006;127(4):697–708. doi:10.1016/j.cell.2006.09.036
   PubMed Web of Science ®Google Scholar
• Kim K, Boo K, Yu YS, et al. RORα controls hepatic lipid homeostasis via negative regulation of PPARγ transcriptional network. Nat Commun. 2017;8(1):1–15. doi:10.1038/s41467-016-0009-6
   PubMedGoogle Scholar
• Sun X, Dongol S, Qiu C, et al. miR-652 promotes tumor proliferation and metastasis by targeting RORA in endometrial cancer. Mol Cancer Res. 2018;16(12):1927–1939. doi:10.1158/1541-7786.MCR-18-0267
   PubMed Web of Science ®Google Scholar
• Oh SK, Kim D, Kim K, et al. RORα is crucial for attenuated inflammatory response to maintain intestinal homeostasis. Proc Natl Acad Sci. 2019;116(42):21140–21149. doi:10.1073/pnas.1907595116
   PubMed Web of Science ®Google Scholar
• Yang XO, Pappu BP, Nurieva R, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity. 2008;28(1):29–39. doi:10.1016/j.immuni.2007.11.016
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–1214. doi:10.1056/NEJMoa1900750
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ferrante M, Bhandari BR, et al. Efficacy and safety of mirikizumab in a randomized Phase 2 study of patients with ulcerative colitis. Gastroenterology. 2020;158(3):537–549. e510. doi:10.1053/j.gastro.2019.08.043
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, D’Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699–1709. doi:10.1016/S0140-6736(17)30570-6
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–1700. doi:10.1136/gutjnl-2011-301668
   PubMed Web of Science ®Google Scholar
• Martin DA, Churchill M, Flores-Suarez LF, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther. 2013;15(5):R164. doi:10.1186/ar4347
   PubMed Web of Science ®Google Scholar
• Wang R, Campbell S, Amir M, et al. Genetic and pharmacological inhibition of the nuclear receptor RORα regulates TH 17 driven inflammatory disorders. Nat Commun. 2021;12(1):1–18. doi:10.1038/s41467-020-20314-w
   PubMed Web of Science ®Google Scholar
• Son H-J, Lee SH, Lee S-Y, et al. Oncostatin M suppresses activation of IL-17/Th17 via SOCS3 regulation in CD4+ T cells. J Immunol. 2017;198(4):1484–1491. doi:10.4049/jimmunol.1502314
   PubMed Web of Science ®Google Scholar
• Tao Y, Zhang X, Chopra M, et al. The role of endogenous IFN-β in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis. J Immunol. 2014;192(12):5610–5617. doi:10.4049/jimmunol.1302580
   PubMed Web of Science ®Google Scholar
• Jetten AM. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl Recept Signal. 2009;7(1):nrs.07003. doi:10.1621/nrs.07003
   PubMedGoogle Scholar
• Cook DN, Kang HS, Jetten AM. Retinoic acid-related orphan receptors (RORs): regulatory functions in immunity, development, circadian rhythm, and metabolism. Nuclear Recept Res. 2015;2. doi:10.11131/2015/101185
   PubMedGoogle Scholar
• Hams E, Roberts J, Bermingham R, Fallon PG. Functions for retinoic acid-related orphan receptor alpha (RORα) in the activation of macrophages during lipopolysaccharide-induced septic shock. Front Immunol. 2021;12:612. doi:10.3389/fimmu.2021.647329
   Web of Science ®Google Scholar
• Ferreira AC, Szeto AC, Heycock MW, et al. RORα is a critical checkpoint for T cell and ILC2 commitment in the embryonic thymus. Nat Immunol. 2021;22(2):166–178. doi:10.1038/s41590-020-00833-w
   PubMed Web of Science ®Google Scholar
• Lee J-E, Choi G, Cho M, Kim D, Lee M-O, Chung Y. A critical regulation of Th2 cell responses by RORα in allergic asthma. Sci China Life Sci. 2020;64:1–10.
   PubMed Web of Science ®Google Scholar
• Malhotra N, Leyva-Castillo JM, Jadhav U, et al. RORα-expressing T regulatory cells restrain allergic skin inflammation. Sci Immunol. 2018;3(21). doi:10.1126/sciimmunol.aao6923
   PubMed Web of Science ®Google Scholar
• Capone A, Volpe E. Transcriptional regulators of T helper 17 cell differentiation in health and autoimmune diseases. Front Immunol. 2020;11:348. doi:10.3389/fimmu.2020.00348
   PubMed Web of Science ®Google Scholar
• Castro G, Liu X, Ngo K, et al. RORγt and RORα signature genes in human Th17 cells. PLoS One. 2017;12(8):e0181868. doi:10.1371/journal.pone.0181868
   PubMed Web of Science ®Google Scholar
• Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res. 2019;2019:1–16. doi:10.1155/2019/7247238
   Web of Science ®Google Scholar
• Rismo R, Olsen T, Cui G, Christiansen I, Florholmen J, Goll R. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scand J Gastroenterol. 2012;47(5):538–547. doi:10.3109/00365521.2012.667146
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Okamoto S, Hisamatsu T, et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut. 2008;57(12):1682–1689. doi:10.1136/gut.2007.135053
   PubMed Web of Science ®Google Scholar
• Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14(5):269–278. doi:10.1038/nrgastro.2016.208
   PubMed Web of Science ®Google Scholar
• Liang T, Chen T, Qiu J, et al. Inhibition of nuclear receptor RORα attenuates cartilage damage in osteoarthritis by modulating IL-6/STAT3 pathway. Cell Death Dis. 2021;12(10):1–13. doi:10.1038/s41419-021-04170-0
   PubMed Web of Science ®Google Scholar
• Chi X, Jin W, Bai X, et al. RORα is critical for mTORC1 activity in T cell-mediated colitis. Cell Rep. 2021;36(11):109682. doi:10.1016/j.celrep.2021.109682
   PubMed Web of Science ®Google Scholar
• Haim-Vilmovsky L, Henriksson J, Walker JA, et al. Mapping Rora expression in resting and activated CD4+ T cells. PLoS One. 2021;16(5):e0251233. doi:10.1371/journal.pone.0251233
   PubMed Web of Science ®Google Scholar
• Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1756–1767. e1751. doi:10.1053/j.gastro.2011.02.016
   PubMed Web of Science ®Google Scholar
• Imam T, Park S, Kaplan MH, Olson MR. Effector T helper cell subsets in inflammatory bowel diseases. Front Immunol. 2018;9:1212. doi:10.3389/fimmu.2018.01212
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol. 2014;11(4):243–255. doi:10.1038/nrgastro.2013.253
   PubMed Web of Science ®Google Scholar
• Martin JC, Chang C, Boschetti G, et al. Single-cell analysis of Crohn’s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy. Cell. 2019;178(6):1493–1508. e1420. doi:10.1016/j.cell.2019.08.008
   PubMed Web of Science ®Google Scholar
• Schmitt H, Billmeier U, Dieterich W, et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease. Gut. 2019;68(5):814–828. doi:10.1136/gutjnl-2017-315671
   PubMed Web of Science ®Google Scholar